Gemcitabine-induced pulmonary toxicity during adjuvant therapy in a patient with pancreatic cancer

Journal of the Pancreas

Volumn 9, Issue 6, 2008, Pages 708-714

  Shaib, Walid ^a   Lansigan, Frederick ^a   Cornfield, Daniel ^a   Syrigos, Kostas ^a   Saif, Muhammad Wasif ^a,b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Division of Medical Oncology   (United States)

Author keywords

Bronchiolitis obliterans organizing pneumonia; Gemcitabine; Pancreatic neoplasms; Pneumonia

Indexed keywords

ANTIBIOTIC AGENT; CAPECITABINE; CEFTRIAXONE; DOXYCYCLINE; GEMCITABINE; STEROID;

AGED; ARTICLE; BACTERIAL PNEUMONIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COMMUNITY ACQUIRED PNEUMONIA; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; HUMAN; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MONOTHERAPY; OXYGEN SATURATION; PANCREAS CANCER; PANCREATICODUODENECTOMY; PNEUMONIA; POSTOPERATIVE PERIOD; VIRUS PNEUMONIA; WOUND DEHISCENCE;

ADENOCARCINOMA; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; DIAGNOSIS, DIFFERENTIAL; FLUOROURACIL; HUMANS; LUNG; MALE; OXYGEN INHALATION THERAPY; PANCREATIC NEOPLASMS; PNEUMONIA; TOMOGRAPHY, X-RAY COMPUTED;

EID: 56849101763     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Steer M. Clinical manifestations, diagnosis, and surgical staging of exocrine pancreatic cancer. UpToDate. 2008; version 16.2.
2. Oettle H, Post S, Neuhaus P, et al. Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 2007; 297:267-77.
3. Regine WF, Winter KA, Abrams RA, et al. Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008; 299:1019-26.
4. Neuhaus P, Riess H, Post S, et al. CONKO-001: Final results of the randomized, prospective, multicenter phase III trial of adjuvant chemotherapy with gemcitabine versus observation with resected pancreatic cancer. JCO 2008; 26(May 20 suppl, LBA4504).
5. Burris HA, 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15:2403-13.
6. Prescribing information, Gemzar (Gemcitabine HCL), for Injection, 1998.
7. Roychowdhury DF, Cassidy CA, Peterson P, Arning M. A report on serious pulmonary toxicity associated with gemcitabine-based therapy. Invest New Drugs 2002; 20:311-5.
8. National Cancer Institute, U.S. National Institute of Health. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). http://ctep.cancer.gov/reporting/ctc_v30.html (Publish date August 9, 2006).
9. Boeck S, Wilkowski R, Bruns CJ, et al. Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer. Oncology 2007; 73:221-7.
10. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004; 350:1200-10.
11. Chu E, DeVita VT. Physicians' Cancer Chemotherapy Drug Manual 2008. 2008
12. Tempero MA, Brand R. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1998; 82:1800-1.
13. Vermorken JB, Guastalla JP, Hatty SR, et al. Phase I study of gemcitabine using a once every 2 weeks schedule. Br J Cancer 1997; 76:1489-93.
14. Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest 2008; 133:528-38.
15. Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera PL. Diffuse alveolar damage in a patient treated with gemcitabine. Eur Respir J 1998; 11:504-6.
16. Barlesi F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol 2004; 18:85-91.
17. Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy. Oncologist 2001; 6:153-61.
18. Ciotti R, Belotti G, Facchi E, Cantu A, D'Amico A, Gatti C. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine. Ann Oncol 1999; 10:997.
19. Pavlakis N, Bell DR, Millward MJ, Levi JA. Fatal pulmonary toxicity resulting from treatment with gemcitabine. Cancer 1997; 80:286-91.
20. Linskens RK, Golding RP, van Groeningen CJ, Giaccone G. Severe acute lung injury induced by gemcitabine. Neth J Med 2000; 56:232-5.
21. Nomura M, Inoue Y, Fujita S, Sakao J, Hirota M, Souda S. A case of drug-induced interstitial pneumonitis after gemcitabine treatment for advanced pancreatic cancer. Gan To Kagaku Ryoho 2006; 33:123-7.
22. Biswas S, Nik S, Corrie PG. Severe gemcitabine-induced capillary-leak syndrome mimicking cardiac failure in a patient with advanced pancreatic cancer and high-risk cardiovascular disease. Clin Oncol (R Coll Radiol) 2004; 16:577-9.
23. Joerger M, Gunz A, Speich R, Pestalozzi BC. Gemcitabine-related pulmonary toxicity. Swiss Med Wkly 2002; 132:17-20.
24. Sauer-Heilborn A, Kath R, Schneider CP, Hoffken K. Severe non-haematological toxicity after treatment with gemcitabine. J Cancer Res Clin Oncol 1999; 125:637-40.
25. Ho Kim D, Shiozawa S, Tsuchiya A, et al. A case of drug-induced interstitial pneumonitis after adjuvant chemotherapy with gemcitabine for pancreatic cancer. Gan To Kagaku Ryoho 2008; 35:133-6.